IGF-1 DES and IGF-1 LR3 are engineered variants of the same 70 amino acid growth factor, modified in opposite directions: one truncated to act as a fast local pulse, the other extended to circulate for a day or more. The published record treats the choice between them as a match between a molecule's kinetic profile and a research question, not a ranking of better versus worse, and the honest bottom line is that both are research reagents with no approved human use and a shared safety profile set by the receptor they both hit.
| Property | IGF-1 DES | IGF-1 LR3 |
|---|---|---|
| Modification | N-terminal tripeptide removed (67 aa) | 13 aa extension plus Arg-3 substitution |
| Half-life | Minutes | ~20 to 30 hours |
| Binding-protein affinity | Sharply reduced | Weak |
| Reported potency | Highest effective potency | Lower per-molecule, higher total exposure |
| Action profile | Rapid, local | Sustained, systemic |
IGF-1 DES carries a half-life measured in minutes while IGF-1 LR3 persists for roughly 20 to 30 hours, and both are sold only as research reagents with no approved human therapeutic use.
The three forms diverge almost entirely at the N-terminus while sharing an identical folded core, and that one region is what determines whether a variant is recognized by the IGF binding proteins. Native IGF-1 keeps its intact glycine-proline-glutamate tripeptide, DES cleaves it off, and LR3 buries it under a 13 amino acid extension plus an arginine-for-glutamate swap at position 3.
DES(1-3)IGF-1 is a 67 amino acid truncation missing the N-terminal glycine-proline-glutamate, while IGF-1 LR3 adds a 13 amino acid extension and an arginine-3 substitution to the otherwise intact 70 amino acid sequence.
Both analogs escape the binding proteins, yet they land in opposite time domains, and that is the subtlety the shorthand blurs. The six binding proteins normally hold most IGF-1 in an inactive reservoir and release only a small free fraction, so DES loses that protection and is cleared almost as fast as it appears, while LR3 owes its endurance to an engineered backbone that resists proteolysis rather than to any binding-protein shielding.
| Property | IGF-1 DES | IGF-1 LR3 |
|---|---|---|
| Free vs bound | Mostly free immediately | Mostly free |
| Half-life | Minutes | ~20 to 30 hours |
| Reason for its duration | No reservoir, rapid clearance | Proteolysis-resistant backbone |
| Protocol dosing pattern | Frequent or local application | Infrequent administration |
IGF-1 DES sheds binding-protein affinity and is cleared within minutes for lack of a protective reservoir, whereas IGF-1 LR3 is equally free of binding proteins yet persists 20 to 30 hours because its engineered backbone resists clearance.
The kinetic gap reads straight through into where each molecule can act. Cleared in minutes, DES drives an intense but geographically contained burst of signaling before it disappears; persisting for a day or more, LR3 distributes body-wide and holds receptor activation elevated across many tissues at once.
The minutes-long clearance of IGF-1 DES confines its action to an intense local burst, while the 20-to-30-hour persistence of IGF-1 LR3 produces sustained, body-wide receptor activation.
A clean potency ranking is misleading, because the number depends on whether the molecule is measured alone or alongside binding proteins. At the receptor itself the three forms bind through the same recognition surface and have broadly comparable intrinsic affinity; the differences that get reported come almost entirely from binding-protein interference and from how long each molecule lasts.
The intrinsic IGF-1 receptor affinities of native IGF-1, DES, and LR3 are broadly comparable, so the reputation of DES as the most potent reflects its escape from binding proteins under assay conditions rather than a higher raw receptor affinity.
On the regulatory axis the engineered analogs and the one approved drug split sharply. Neither DES nor LR3 is approved as a human therapeutic anywhere; both are labeled strictly as research chemicals, carrying none of the manufacturing, purity, or safety guarantees attached to a licensed medicine, so any benefit claim attached to them rests on preclinical or anecdotal grounds rather than controlled human evidence.
Neither IGF-1 DES nor IGF-1 LR3 is approved as a human therapeutic by any major regulator; both are sold only as research chemicals, while native-sequence recombinant IGF-1 (mecasermin) is the sole approved member and IGF-1 analogs are banned substances in sport.
Analog selection in the published protocols comes down to matching a molecule's kinetic and binding-protein profile to the experimental readout, not to any single best choice. Freedom from binding proteins is often the deciding factor in cell culture, where serum and cellular binding proteins would otherwise sequester native IGF-1 unpredictably, which is a major reason engineered analogs are favored over native-sequence peptide in many in vitro assays.
Researchers match the analog to the readout, choosing the minutes-long DES for brief local signaling, the 20-to-30-hour LR3 for sustained systemic exposure, and native-sequence recombinant IGF-1 when the goal is to model binding-protein physiology faithfully.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 DES and IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
